Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Repligen Corporation reported results for the fourth quarter and fiscal year 2009, ended March 2009. Total revenue for fiscal year 2009 was $29,362,000 compared to total revenue of $19,296,000 for fiscal year 2008 ended March 2008, an increase of $10,066,000 or 52%. Total revenue for the year was comprised of Protein A product revenue, and royalty and other revenue. Product revenue for the year was $14,529,000 and royalty and other revenue was $14,833,000, comprised primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia and grant revenue from the Muscular Dystrophy Association. [more...]
|
|
|
